Aim:
To investigate long-term clinical and cost effectiveness of individualised homeopathic and medical treatment of children with attention deficit hyperactivity disorder (ADHD).
Methods:
An open pilot study had revealed sufficient data to develop a randomised, double-blind, placebo-controlled trial (RCT), embedded in a prospective observational study of children with ADHD diagnosis, according to established neuropsychiatric criteria (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)). After a screening run-in phase of homeopathic treatment, the crossover RCT was followed by open-label long-term follow-up. At diagnosis, beginning of, and after each crossover period, and five times in long-term follow-up, parents reported Conners’ Global Index (CGI, 10 items, rated 0-3 points each primary variable) and patients underwent neuropsychological testing (secondary vari- ables) until the end of RCT. Cost comparison (tertiary variable) was done after the clinical trial and during long-term follow-up.
Results:
A total of 83 children between 7 and 15 years were treated with individually prescribed homeopathic remedies. As 13 patients did not improve at least 50% in CGI values (inclusion criterion), the remaining 62 children (84%) participated in, and 58 finished a double-blind cross-over RCT. During this RCT, CGI ratings were significantly lower (average 1.67 points) under verum than under placebo (p = 0.0479). After 17 and 115 months of treatment, long-term global CGI reached 8/30 points, resembling an improvement of more than 50% (p < 0.0001). Specific CGI results (range) after 10 years for children without any therapy, children with homeopathy and children with methylphenidate (MPD) as a single or a combined therapy will be given. Cognitive performance (global visual perception, impulsivity/hyperactivity and learning/attention) and social behaviour improved highly significantly and were stable during follow-up (p = 0.0001-p = 0.0004). Homeopathy costs are 75% of average stimulant therapy (20 mg MPD) in the first, and 50% of 10 mg MPD in following years summing up to CHF 2120 (D 1705) compared to CHF 3650 (D 2920) for the single child with stimulant therapy (average 20 mg day-1) during 10 years.
Conclusion:
In children with ADHD, individualised homeopathic therapy has both, a clinically significant and specific long-lasting effect with duration over 10 years, and may reduce costs to an amount of up to 50%.